Bell R J
Women's Health Research Program, Monash University School of Public Health and Preventive Medicine , Melbourne, Victoria , Australia.
Climacteric. 2014 Dec;17 Suppl 2:66-72. doi: 10.3109/13697137.2014.956718. Epub 2014 Sep 16.
The aim of this review was to examine the benefits and harms of organized screening mammography, with particular reference to data from Australia.
Published literature was examined relating to the impact of screening mammography on breast cancer-specific mortality, the trends in use of adjuvant treatments for breast cancer, the effectiveness of adjuvant treatment in terms of breast cancer-specific mortality, the impact of breast cancer treatment on non-breast cancer mortality and the magnitude of the issue of over-diagnosis.
Most of the recent reduction in breast cancer-specific mortality is explained by use of adjuvant therapy rather than screening mammography. The impact of screening mammography in countries where women present with early disease and have access to adjuvant treatment is modest. There is a wide range of estimates for the magnitude of over-diagnosis. All-cause mortality (rather than breast cancer-specific mortality) should be used when assessing the impact of mammographic screening as otherwise the harm of breast cancer treatment in women who are over-diagnosed will be missed.
The benefits and harms of screening mammography are finely balanced. The impact of screening mammography is at best neutral but may result in overall harm. Women should be informed of the issue of over-diagnosis. It is time to review whether organized mammographic screening programs should continue.
本综述旨在探讨有组织的乳腺钼靶筛查的益处和危害,特别参考澳大利亚的数据。
查阅已发表的文献,内容涉及乳腺钼靶筛查对乳腺癌特异性死亡率的影响、乳腺癌辅助治疗的使用趋势、辅助治疗在乳腺癌特异性死亡率方面的有效性、乳腺癌治疗对非乳腺癌死亡率的影响以及过度诊断问题的严重程度。
近期乳腺癌特异性死亡率的下降主要是由于辅助治疗的使用,而非乳腺钼靶筛查。在女性所患疾病为早期且可获得辅助治疗的国家,乳腺钼靶筛查的影响不大。对于过度诊断的严重程度,有多种不同的估计。在评估乳腺钼靶筛查的影响时,应使用全因死亡率(而非乳腺癌特异性死亡率),否则会忽略过度诊断女性中乳腺癌治疗的危害。
乳腺钼靶筛查的益处和危害权衡微妙。乳腺钼靶筛查的影响充其量是中性的,但也可能导致总体危害。应告知女性过度诊断的问题。是时候审视有组织的乳腺钼靶筛查项目是否应继续开展了。